Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peptide X
- Development stage
- Preclinical
- Lead developer
- Centre Européen d'Étude du Diabète
- Modality
- Peptides
01
Overview
Peptide X is an experimental therapeutic peptide under preclinical development by the Centre Européen d'Etude du Diabète (CEED) and Tohoku University for the treatment of diabetes. It acts as an inhibitor of MP001, a protein specific to pancreatic β-cells that plays a key role in insulin granule exocytosis and cellular remodeling. By inhibiting MP001, Peptide X has been shown to improve human pancreatic islet survival and function in vitro, enhancing glucose-stimulated insulin secretion and upregulating key survival and insulin signaling pathways, including Akt, IRS1, IRS2, and AS160.
Beyond the preview
Go deeper on Peptide X.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peptide X.